Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted CysLTR1 Blockade Rescues Myeloid-Mediated Resistance to Immune Checkpoint Inhibition in Solid Malignancies: A Combined Genomic, Emulated Clinical Trial, and Epidemiological Negative-Control Analysis.

American journal of clinical oncology·2026
Same author

<i>CDKN2A</i> mRNA Over-expression Is Associated With CD8+ T Cell Exclusion and IDO1-Mediated Adaptive Immune Resistance in Gastric Adenocarcinoma.

Cancer diagnosis & prognosis·2026
Same author

Multi-Layered Dysregulation of NRCAM in Lower-Grade Gliomas: Insights From TCGA Copy Number and Epigenetic Analyses.

Brain tumor research and treatment·2026
Same author

RAP1A Variant rs7525578 Modifies Glycemic Response to Metformin But Not to Pioglitazone or Gliclazide in the UK Biobank.

Clinical neuropharmacology·2026
Same author

RE: Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.

Journal of the National Cancer Institute·2026
Same author

FOXA1 Alterations in Prostate Cancer: Expression, Mutation Classes, and Copy Number Changes.

In vivo (Athens, Greece)·2026

Related Experiment Video

Updated: Jul 11, 2026

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

A Sequential Proteomic Relay Defines a Decade-long Pre-diagnostic Window for Pancreatic Cancer.

Steven Lehrer1, Peter H Rheinstein2

  • 1Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.

Cancer Diagnosis & Prognosis
|March 4, 2026
PubMed
Summary

Researchers identified a decade-long proteomic countdown for pancreatic cancer, with specific protein changes years before diagnosis. This discovery enables earlier detection and intervention for this deadly disease.

Keywords:
Pancreatic ductal adenocarcinomaUK Biobankbiomarker trajectoriesearly cancer detectionplasma proteomics

More Related Videos

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jul 11, 2026

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Area of Science:

  • Proteomics
  • Biomarker Discovery
  • Cancer Research

Background:

  • Pancreatic adenocarcinoma presents late, leading to high mortality.
  • Lack of early biomarkers hinders timely intervention.
  • Identifying pre-diagnostic signals is crucial for improving outcomes.

Purpose of the Study:

  • To identify and characterize circulating proteomic biomarkers that change systematically before pancreatic cancer diagnosis.
  • To determine if these protein trajectories define distinct pre-diagnostic risk windows for earlier interception.

Main Methods:

  • Utilized longitudinal proteomic data from the UK Biobank.
  • Employed hinge-regression change-point modeling to find temporal protein inflection points.
  • Partitioned the pre-diagnostic period into "Far" (5-10 years) and "Near" (0-5 years) windows.

Main Results:

  • Identified a sequential "relay" of protein trajectories, with CTHRC1 as an early signal (8.93 years pre-diagnosis) and RELT as a later signal (2 years pre-diagnosis).
  • The integrated proteomic model achieved an Adjusted R² of 0.434 and an AUC of 0.814.
  • The model distinguished pre-diagnostic windows with 87.5% precision and 80.0% specificity at an optimal threshold.

Conclusions:

  • Pancreatic cancer exhibits a predictable, decade-long proteomic signature.
  • This staged relay model offers a framework for risk-stratified surveillance.
  • The findings extend the window for clinical action significantly beyond current standards.